Vanessa Williams Says Two Years on Mounjaro Helped With Menopause-Related Weight Gain

Overview

• The 62-year-old told Hello! magazine she has been on the GLP-1 tirzepatide, marketed as Mounjaro, for about two years and called it “a game-changer.”
• She said perimenopause began in her late 40s and that in her early 50s her body no longer responded to the same diet and workouts.
• Williams added that she is on hormone replacement therapy and recently began NAD+ injections as part of her regimen.
• Mounjaro is FDA-approved for type 2 diabetes, and its weight-loss effects have increased interest in GLP-1 therapies, with the related brand Zepbound cleared for chronic weight management.
• Her disclosure joins a wave of celebrity acknowledgments of GLP-1 use, with figures such as Rosie O’Donnell and Meghan Trainor publicly discussing the medications.